Hologic, Inc. (NASDAQ:HOLX) Shares Sold by Alan B Lancz & Associates Inc.

Alan B Lancz & Associates Inc. lessened its stake in Hologic, Inc. (NASDAQ:HOLX) by 10.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,450 shares of the medical equipment provider’s stock after selling 500 shares during the period. Alan B Lancz & Associates Inc.’s holdings in Hologic were worth $321,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Public Sector Pension Investment Board raised its stake in shares of Hologic by 92.5% in the 2nd quarter. Public Sector Pension Investment Board now owns 8,759 shares of the medical equipment provider’s stock valued at $650,000 after purchasing an additional 4,208 shares in the last quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp increased its holdings in Hologic by 56.9% in the second quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 44,963 shares of the medical equipment provider’s stock valued at $3,339,000 after buying an additional 16,307 shares during the last quarter. Squarepoint Ops LLC raised its stake in Hologic by 251.9% during the second quarter. Squarepoint Ops LLC now owns 58,880 shares of the medical equipment provider’s stock valued at $4,372,000 after buying an additional 97,634 shares in the last quarter. AQR Capital Management LLC lifted its holdings in Hologic by 1.5% during the 2nd quarter. AQR Capital Management LLC now owns 565,955 shares of the medical equipment provider’s stock worth $42,022,000 after buying an additional 8,441 shares during the last quarter. Finally, APG Asset Management N.V. grew its position in shares of Hologic by 2.2% in the 2nd quarter. APG Asset Management N.V. now owns 360,093 shares of the medical equipment provider’s stock worth $24,947,000 after acquiring an additional 7,828 shares in the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, COO Essex D. Mitchell sold 24,856 shares of Hologic stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the transaction, the chief operating officer now directly owns 27,957 shares in the company, valued at approximately $2,134,237.38. This trade represents a 47.06 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.88% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. BNP Paribas upgraded Hologic to a “strong-buy” rating in a research note on Tuesday, December 10th. Raymond James lifted their price target on shares of Hologic from $93.00 to $95.00 and gave the company an “outperform” rating in a report on Tuesday, November 5th. Jefferies Financial Group initiated coverage on shares of Hologic in a research note on Tuesday, December 10th. They set a “hold” rating and a $85.00 price objective on the stock. Needham & Company LLC restated a “buy” rating and issued a $90.00 target price on shares of Hologic in a research note on Monday, January 13th. Finally, StockNews.com upgraded Hologic from a “hold” rating to a “buy” rating in a research report on Thursday, November 14th. Seven equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $88.92.

Hologic Trading Up 0.5 %

NASDAQ:HOLX opened at $71.02 on Friday. Hologic, Inc. has a 1 year low of $68.61 and a 1 year high of $84.67. The business has a fifty day moving average of $74.01 and a 200-day moving average of $78.25. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.03 and a current ratio of 3.69. The stock has a market cap of $16.03 billion, a price-to-earnings ratio of 21.33, a PEG ratio of 2.43 and a beta of 0.97.

Hologic (NASDAQ:HOLX) last released its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, meeting the consensus estimate of $1.01. The firm had revenue of $987.90 million for the quarter, compared to analysts’ expectations of $978.25 million. Hologic had a net margin of 19.59% and a return on equity of 19.79%. Hologic’s quarterly revenue was up 4.5% on a year-over-year basis. During the same quarter last year, the company earned $0.89 EPS. Equities analysts predict that Hologic, Inc. will post 4.27 earnings per share for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.